- Company
- Will the SGLT-2i Jardiance be reimb for CKD in 2H?
- by Eo, Yun-Ho Aug 23, 2024 06:18am
- Attention is focused on whether the SGLT-2 inhibitor Jardiance can settle as a reimbursed prescription option for chronic kidney disease in the second half of the year. According to industry sources, the Health Insurance Review and Assessment Service is currently reviewing the reimbursement expansion of Boehringer Ingelheim and Lilly Kore
- Policy
- DREC to review the COVID-19 drug Paxlovid a week earlier
- by Lee, Tak-Sun Aug 23, 2024 06:17am
- The Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) will convene a week earlier than scheduled. The DREC review evaluates the appropriateness of new drugs for reimbursement. Industry analysis suggests that the schedule has changed to quickly list the COVID-19 treatment 'Paxlovid
- Company
- Yungjin applies for approval of its Ofev generic
- by Hwang, Byung-woo Aug 23, 2024 06:17am
- Yungjin Pharmaceutical announced on the 22nd that it has completed the license application for a generic version of Boehringer Ingelheim's ‘Ofev Soft Cap (Ofev)’ that it had developed by changing the original drug’s soft capsule formulation into a tablet. As a global blockbuster product, Ofev (nintedanib) is widely used in combination
- Policy
- Ildong to continue oral 'GLP-1 receptor agonist' trial
- by Lee, Hye-Kyung Aug 22, 2024 05:55am
- Ildong Pharmaceutical will conduct an additional round of Phase 1 clinical trial for its proprietary new drug candidate, 'ID110521156,' for the treatment of type 2 diabetes. The drug, by the development code ID110521156, is an oral new drug targeting type 2 diabetes and obesity. On August 20th, the Ministry of Food and Drug Safety (
- Company
- Yuhan’s Leclaza enters US 6yrs after signing licensing deal
- by Chon, Seung-Hyun Aug 22, 2024 05:50am
- Yuhan Corp’s new anticancer drug Leclaza has successfully entered the U.S. market. The drug has reached the commercialization stage 6 years after licensing out its technology to Janssen. As a result, the company will receive USD 60 million as a milestone payment with Leclaza’s approval in the U.S. The company has earned nearly KRW 300 billion
- Company
- Bavencio shows clear benefit in urothelial cancer
- by Hwang, Byung-woo Aug 22, 2024 05:50am
- The treatment landscape for metastatic urothelial cell carcinoma has changed after Bavencio (avelumab) was granted reimbursement as a first-line maintenance therapy in Korea. Bavencio addressed the high unmet need that had remained for a maintenance therapy option on site, rapidly changing the prescribing pattern. Merck Biopharma Korea
- Company
- MET-targeting anticancer drug 'Tepmetko' prescribed at Big 5
- by Eo, Yun-Ho Aug 22, 2024 05:50am
- The MET-targeting anticancer drug 'Tepmetko' is now available for prescription at general hospitals. Sources said that Merck Korea's Tepmetko (tepotinib), a treatment for patients with topically advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping mutat
- Policy
- Preferential pricing delayed for homegrown new drugs
- by Lee, Tak-Sun Aug 22, 2024 05:50am
- The delay in issuance of a revised draft that includes preferential drug pricing measures for domestic new drugs is raising concerns in the pharmaceutical industry. This month, a revised draft that reflects the innovative value of new drugs was released by the Health Insurance Review and Assessment Service, but the revision lacked a measu
- Policy
- Takeda receives P3T approval for TAK-861 in Korea
- by Lee, Hye-Kyung Aug 21, 2024 05:48am
- The Japanese pharmaceutical company Takeda Pharmaceuticals will enter Phase III clinical trials for TAK-861, its new drug candidate for narcolepsy, in Korea. On the 20th, the Ministry of Food and Drug Safety (MFDS) on Tuesday approved a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safe
- Company
- SCLC drug tarlatamab may soon be introduced in KOR
- by Eo, Yun-Ho Aug 21, 2024 05:48am
- Amgen is preparing to introduce its new small cell lung cancer drug tarlatamab in Korea. According to industry sources, Amgen Korea has submitted an application for tarlatamab, its bispecific antibody for small cell lung cancer, to the Ministry of Food and Drug Safety and is undergoing review. The drug was designated the first orphan
